Rachelle D Rodriguez, Ashley E L Anderson, Kelly G Gwathmey, Caroline R Brethenoux, Lisa M Shea, Raghav Govindarajan, Nizar Souayah, Wesley D Peters, Louis A Jackson, Zia U Choudhry
{"title":"Mental Health Experiences and Challenges Among Individuals with Myasthenia Gravis: Insights from Patient-Centered, Qualitative Analyses.","authors":"Rachelle D Rodriguez, Ashley E L Anderson, Kelly G Gwathmey, Caroline R Brethenoux, Lisa M Shea, Raghav Govindarajan, Nizar Souayah, Wesley D Peters, Louis A Jackson, Zia U Choudhry","doi":"10.1007/s12325-025-03399-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Historically, anxiety and depression rates have been higher among individuals with myasthenia gravis (MG) than the general population, and self-reported sentiments and experiences of mental health impairment may be more common than formal diagnoses. Patient-centered research can provide insight into self-described anxiety and depressive symptoms and stressors experienced by those with MG in the United States (US) and improve understanding of the current prevalence of anxiety and depression.</p><p><strong>Methods: </strong>Insights were collected from three sources. First, a literature review of quantitative and/or real-world studies of anxiety/depression among individuals with gMG in the US. Second, a secondary, qualitative analysis of the transcripts from focus groups conducted with 12 individuals with self-reported generalized MG. Third, analysis of thousands of online conversations between people with self-reported ocular or generalized MG using search, data extraction, and artificial intelligence-powered algorithms. No statistical analyses were performed.</p><p><strong>Results: </strong>The literature review identified three studies (precluding a meta-analysis): prevalence estimates for depression were 19% (diagnosed), 31% (receiving antidepressants), and 75% (self-reported sentiments), and for anxiety were 17%, 19% (both diagnosed), and 82% (self-reported sentiments). Unique stressors and triggers were identified, classified into four categories: experience of symptoms/uncontrolled symptoms; burden of medical care; daily life functioning, responsibilities, and aspirations; and social support needs. The relative prominence of each stressor and its induced emotion varied by stage in the disease journey: fear and anxiety were discussed more frequently prior to MG diagnosis, whereas hopelessness and depression became more prominent later, during ongoing disease monitoring and management. Patients felt that stress worsened symptoms in a positive feedback loop.</p><p><strong>Conclusion: </strong>This qualitative, hypothesis-generating study found that individuals with MG in the US were more likely to report experiencing anxiety and depression than the general population due, at least in part, to their MG-specific disease journey and the uncontrolled symptoms experienced.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03399-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Historically, anxiety and depression rates have been higher among individuals with myasthenia gravis (MG) than the general population, and self-reported sentiments and experiences of mental health impairment may be more common than formal diagnoses. Patient-centered research can provide insight into self-described anxiety and depressive symptoms and stressors experienced by those with MG in the United States (US) and improve understanding of the current prevalence of anxiety and depression.
Methods: Insights were collected from three sources. First, a literature review of quantitative and/or real-world studies of anxiety/depression among individuals with gMG in the US. Second, a secondary, qualitative analysis of the transcripts from focus groups conducted with 12 individuals with self-reported generalized MG. Third, analysis of thousands of online conversations between people with self-reported ocular or generalized MG using search, data extraction, and artificial intelligence-powered algorithms. No statistical analyses were performed.
Results: The literature review identified three studies (precluding a meta-analysis): prevalence estimates for depression were 19% (diagnosed), 31% (receiving antidepressants), and 75% (self-reported sentiments), and for anxiety were 17%, 19% (both diagnosed), and 82% (self-reported sentiments). Unique stressors and triggers were identified, classified into four categories: experience of symptoms/uncontrolled symptoms; burden of medical care; daily life functioning, responsibilities, and aspirations; and social support needs. The relative prominence of each stressor and its induced emotion varied by stage in the disease journey: fear and anxiety were discussed more frequently prior to MG diagnosis, whereas hopelessness and depression became more prominent later, during ongoing disease monitoring and management. Patients felt that stress worsened symptoms in a positive feedback loop.
Conclusion: This qualitative, hypothesis-generating study found that individuals with MG in the US were more likely to report experiencing anxiety and depression than the general population due, at least in part, to their MG-specific disease journey and the uncontrolled symptoms experienced.
期刊介绍:
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.